Evidence mapPaperPMID 3056758Full record

ReviewDiabetes1988

Banting lecture 1988. Role of insulin resistance in human disease.

G M Reaven

7 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetes, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 2,519 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,519citing papers in PubMed, 8 pooled it
58.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02437084 phase4completedstarted 2015, after this paper: background citation

Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

Ran2015Enrolled115Registered outcomes6Posted comparisons6ConditionsHyperlipidemia, Insulin Resistance, Type 2 DiabetesArmsAtorvastatin
Open the trial in the graph
NCT03031821 phase3terminatedstarted 2018, after this paper: background citation

A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study

Ran2018Enrolled166Registered outcomes30Posted comparisons0ConditionsMetabolic Syndrome, Prostate CancerArmsMetformin, Placebo Oral Tablet
Open the trial in the graph
NCT00161174 completednot on this mapstarted 2005, after this paper: background citation

Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity. (KWF RUG 2004-3157)

TypeobservationalSponsorUniversity Medical Center GroningenRan2005 to 2011Enrolled173ConditionsNon-seminomatous Testicular Cancer
NCT00186537 nacompletednot on this mapstarted 2003, after this paper: background citation

Comparison Fenofibrate, Rosiglitazone, or Weight Loss to Decrease Cardiovascular Risk in Insulin Resistant Dyslipidemic Individuals.

TypeinterventionalSponsorStanford UniversityRan2003 to 2008Enrolled47ConditionsInsulin Resistance, HypertriglyceridemiaArmsRosiglitazone, Fenofibrate, Weight Loss
NCT01168700 phase4unknown statusnot on this mapstarted 2009, after this paper: background citation

A prospective, randomized, double-blind, placebo-controlled trial of the supplementation with kiolic® in patients with diagnosis of metabolic syndrome to improve endothelial function and inflammatory state. "kymes"

TypeinterventionalSponsorUniversidad de SantanderRan2009 to 2010Enrolled46ConditionsMetabolic SyndromeArmsaged garlic extract, Placebo
NCT03325933 naterminatednot on this mapstarted 2017, after this paper: background citation

Resistance Training and Cardiometabolic Health

TypeinterventionalSponsorArizona State UniversityRan2017 to 2020Enrolled62ConditionsInsulin Sensitivity, Endothelial Dysfunction, Blood PressureArmsHigh Load/Low Rep Resistance Training, Low Load/High Rep Resistance Training
NCT06040164 unknown statusnot on this mapstarted 2023, after this paper: background citation

Molecular Study of Oral Dysbacteriosis in People With Prediabetes and Diabetes

TypeobservationalSponsorFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludRan2023 to 2024Enrolled60ConditionsPreDiabetes, Diabetes Mellitus, Type 2, Obesity, Oral DysbiosisArmsObservational study
3 · Its place in the literature

Who cites it

2,519 citing papers in PubMed, 8 syntheses or guidelines pooled it, 12,123 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

2,459 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

G M ReavenDepartment of Medicine, Stanford University Medical Center, California.
Stanford Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to insulin-stimulated glucose uptake is present in the majority of patients with impaired glucose tolerance (IGT) or non-insulin-dependent diabetes mellitus (NIDDM) and in approximately 25% of nonobese individuals with normal oral glucose tolerance. In these conditions, deterioration of glucose tolerance can only be prevented if the beta-cell is able to increase its insulin secretory response and maintain a state of chronic hyperinsulinemia. When this goal cannot be achieved, gross decompensation of glucose homeostasis occurs. The relationship between insulin resistance, plasma insulin level, and glucose intolerance is mediated to a significant degree by changes in ambient plasma free-fatty acid (FFA) concentration. Patients with NIDDM are also resistant to insulin suppression of plasma FFA concentration, but plasma FFA concentrations can be reduced by relatively small increments in insulin concentration. Consequently, elevations of circulating plasma FFA concentration can be prevented if large amounts of insulin can be secreted. If hyperinsulinemia cannot be maintained, plasma FFA concentration will not be suppressed normally, and the resulting increase in plasma FFA concentration will lead to increased hepatic glucose production. Because these events take place in individuals who are quite resistant to insulin-stimulated glucose uptake, it is apparent that even small increases in hepatic glucose production are likely to lead to significant fasting hyperglycemia under these conditions. Although hyperinsulinemia may prevent frank decompensation of glucose homeostasis in insulin-resistant individuals, this compensatory response of the endocrine pancreas is not without its price. Patients with hypertension, treated or untreated, are insulin resistant, hyperglycemic, and hyperinsulinemic. In addition, a direct relationship between plasma insulin concentration and blood pressure has been noted. Hypertension can also be produced in normal rats when they are fed a fructose-enriched diet, an intervention that also leads to the development of insulin resistance and hyperinsulinemia. The development of hypertension in normal rats by an experimental manipulation known to induce insulin resistance and hyperinsulinemia provides further support for the view that the relationship between the three variables may be a causal one.(ABSTRACT TRUNCATED AT 400 WORDS)

Indexed as

Insulin ResistanceCoronary DiseaseDiabetes Mellitus, Type 2HumansHypertension

Identifiers

PMID3056758
OpenAlexW2096773810

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.